Nanjing Medical Loses 10 Million Yuan In Medical Trust
This article was originally published in PharmAsia News
Nanjing city government started reforming nine municipal third-tier hospitals at the end of May but without the medical trust model it has been advocating. An informed source discloses that participating company Nanjing Medical lost over 10 million yuan in 2007 due to the medical trust although it has enlisted more than 100 first- and second-tier hospitals. Pharmaceutical distributors have to transfer 35 percent of their sales revenue as trust expenses to the hospitals, but with more distributors entering the business, the revenue allocation rate has gone up to 53 percent. This could sound the death knell for the medical trust scheme. Meanwhile, Nanjing Medical has denied its losses; research by Shenyin & Wanguo shows the firm's annual medical trust earned a profit of 2-3 percent. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.